A Phase 3, Randomized, Multicenter, Double-Blind Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Meropenem Followed by Optional Oral Therapy for the Treatment of Complicated Urinary Tract Infection (cUTI), Including Acute Pyelonephritis (AP), in Adults

Trial Profile

A Phase 3, Randomized, Multicenter, Double-Blind Study to Evaluate the Efficacy and Safety of Plazomicin Compared With Meropenem Followed by Optional Oral Therapy for the Treatment of Complicated Urinary Tract Infection (cUTI), Including Acute Pyelonephritis (AP), in Adults

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Plazomicin (Primary) ; Meropenem
  • Indications Pyelonephritis; Urinary tract infections
  • Focus Registrational; Therapeutic Use
  • Acronyms EPIC
  • Sponsors Achaogen
  • Most Recent Events

    • 05 Jun 2017 According to an Achaogen media release, data from this study presented at the American Society for Microbiology (ASM) Microbe 2017 Annual Meeting
    • 05 Jun 2017 Results from this trial published in an Achaogen Media Release.
    • 26 May 2017 According to an Achaogen media release, data from this study wll be presented at the American Society for Microbiology (ASM) Microbe 2017 Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top